Loading patent…
AssigneeArena Pharmaceuticals, Inc.
InventorsRobert M. Jones, Juerg Lehmann, Weichao Chen, Jeffrey Edwards, Glen Marquez, Michael E. Morgan, Abu J. M. Sadeque, Sun Hee Kim
Estimating the term…
The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-imethylbenzamide; 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPRI19-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.
A compound selected from the following compounds and pharmaceutically acceptable salts, solvates, and hydrates thereof:
A method for increasing the secretion of an incretin in an individual or increasing a blood incretin level in an individual, or for treating a disorder selected from a GPR119-receptor-related disorder;
A method for increasing the secretion of an incretin in an individual or increasing a blood incretin level in an individual, or for treating a disorder selected from a GPR119-receptor-related disorder;
Dependencies are inferred from the claim text.